Based on the findings from the EURO-SKI trial along with supporting evidence from DESTINY and other studies, Mahon feels confident that TKI cessation will soon be incorporated into various treatment ...

Dr. Mauro: The main risks are straightforward: Treatment cessation under the correct circumstances (proper patient profile and correct monitoring and approach to retreatment) means that this is a ...

MedPage Today: In your 2014 article, you mention that the goal of treatment-free remission for CML after TKI cessation is considered to be the “next frontier.” ...

The yield of detection was significantly higher after TKI cessation for the baseline mutation (mean semi-quantitative index 5.2±6.2 on d0 and 6.1±6.4 on d6/7; p = .043) but not for T790M (p = .46).

"Hopefully, data from EURO-SKI and other TKI-cessation trials made available now can form the basis for guidelines when moving the stop-TKI concept in CML to the clinic," he told .

The EURO-SKI study is a global trial, that is designed to assess the duration of MMR after halting TKI treatment. Of the 755 participants on this trial, Mahon said that the probability of being ...

The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI-naïve and TKI pre-treated patients with ROS1-positive NSCLC. Story Continues and ...

It is safe for some patients with chronic phase chronic myeloid leukemia (CML) to stop tyrosine kinase inhibitors (TKI) and follow with a maintained, deep molecular remission, according to findings ...

François-Xavier Mahon, MD, PhD, of Bordeaux Segalen University, Bordeaux, France; reviewed and summarized some of the recent studies related to TKI cessation in patients with deep molecular ...